海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Metyyliprednisolonin farmakokinetiikka ja -dynamiikka lasten avosydänleikkausten yhteydessä
- Lasten ja nuorten sairaalassa (HUS) hoidettavat 1-12 kk ikäiset avosydänleikkaukseen tulevat potilaat, joilla on sydänvikanan TOF, AVSD tai VSD. Lasten ja nuorten sairaalassa (HUS) hoidettavat korkeintaan 28 päivän ikäiset avosydänleikkaukseen tulevat potilaat, joilla on sydänvikana TGA, HLHS tai IAA. MedDRA version: 9.1 Level: LLT Classification code 10010495 Term: Congenital heart disease NOS
- Finland
- 2008-12-23
Authorised
- Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial. - Anti-VEGF versus RPE-choroid graft
- Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
- Netherlands
- 2008-12-11
Authorised
- Vätskebehandling vid akut diabetessjukdom (Diabetes ketoacidos) - VAD
- Studien kommer bedrivas på akut diabetessjukdom (Diabetisk ketoacidos). Studien kommer att följa patienten från akuten till IVA tills dess att ph>7,3. Gängse praxis angående medicinsk behandling kommer att följas. Grupp 1 kommer få NaCl som vätsketerapi. Grupp 2 kommer få Ringer-Acetat med + 20 Natrium som vätsketerapi. Båda vätskevalen används idag i daglig praxis vid behandling av Diabetisk ketoacidos. MedDRA version: 9.1 Level: LLT Classification code 10012671 Term: Diabetic ketoacidosis
- Sweden
- 2008-08-28
Authorised
- Investigation of Hepatic Tumors with Positron Emission Tomography Using [11C]-Metomidate and [11C]-Acetate Tracers
- This study is planned to determine and compare two new radiotracers (11C-labeled metomidate and acetate) in the detection of malignant and benign hepatic tumors. The detection of hepatocellular carcinoma (HCC) is a challenging and difficult diagnostic problem by conventional methods, especially in cirrhotic patients(1).
- Finland
- 2004-08-05
Authorised
- Maraviroc Immune Recovery Study (MIRS): A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery - MIRS
- HIV-1 infection MedDRA version: 9.1 Level: LLT Classification code 10008919 Term: Chronic HIV infection
- Netherlands
- 2008-07-23
Authorised
- PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT. - ND
- Children 2-16 years old with documented vertical HIV-1 infection MedDRA version: 9.1 Level: LLT Classification code 10010504 Term: Congenital HIV infection
- Italy
- 2008-05-19
Authorised
- A randomized placebo-controlled double blind study to treat BOS.
- -Mortality at 1 and 2 year post diagnosis of BOS -Infection rate during BOS -Evolution of pulmonary function after diagnosis of BOS MedDRA version: 12.1 Level: LLT Classification code 10029888 Term: Obliterative bronchiolitis MedDRA version: 12.1 Level: LLT Classification code 10049202 Term: Bronchiolitis obliterans MedDRA version: 12.1 Level: LLT Classification code 10068805 Term: Follicular bronchiolitis MedDRA version: 12.1 Level: LLT Classification code 10019319 Term: Heart-lung transplant rejection MedDRA version: 12.1 Level: LLT Classification code 10025127 Term: Lung transplant MedDRA version: 12.1 Level: LLT Classification code 10051604 Term: Lung transplant rejection MedDRA version: 12.1 Level: LLT Classification code 10056409 Term: Heart and lung transplant MedDRA version: 12.1 Level: LLT Classification code 10016547 Term: FEV MedDRA version: 12.1 Level: LLT Classification code 10016549 Term: FEV 1 abnormal MedDRA version: 12.1 Level: LLT Classification code 10016550 Term: FEV 1 decreased MedDRA version: 12.1 Level: LLT Classification code 10016553 Term: FEV 1 low
- Belgium
- 2010-09-02
Authorised
- DANTROLEENI KATEKOLIAMIINIHERKÄSSÄ KAMMIOTAKYKARDIASSA
- Catecholaminergic polymorphic ventricular tachycardia br>MedDRA version: 14.1 Level: LLT Classification code 10036095 Term: Polymorphic ventricular tachycardia System Organ Class: 100000004849 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Finland
- 2012-12-04
Authorised
- rifampicine bij longontsteking vermindert de ontstekingsreactie
- Community acquired pneumonia CURB-65 class >1 MedDRA version: 14.1 Level: LLT Classification code 10010120 Term: Community acquired pneumonia System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Netherlands
- 2012-11-19
Authorised
- Resting the pancreas in Cystic Fibrosis
- Cystic Fibrosis Related Diabetes (CFRD) MedDRA version: 14.1 Level: LLT Classification code 10022468 Term: Insulin System Organ Class: 100000004848 ;Therapeutic area: Body processes [G] - Physiological processes [G07]
- United Kingdom
- 2012-11-09
Authorised
- PhArmaCo-kinetics of InFliximab during treatment Induction
- Patients with Crohn disease or Ulcerative Colitis which need biotherapy (antibody against TNF-a);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium
- 2015-11-20
Authorised
- A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment
- The study objective is to evaluate the safety and clinical benefit of NexoBrid in hospitalized children (0-18 years) with deep partial and/or full thickness thermal burns of 1-30% TBSA and to compare NexoBrid to standard of care (SOC). MedDRA version: 19.1 Level: HLT Classification code 10043418 Term: Thermal burns System Organ Class: 100000004863 ;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
- Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, Netherlands, Romania, Slovakia, Spain, Sweden, United Kingdom
- 2014-10-08
Authorised
- A study testing how BI 655130 works in patients with fistulizing Crohn’s Disease
- Fistulizing Crohn’s Disease MedDRA version: 20.0 Level: LLT Classification code 10075465 Term: Fistulizing Crohn's disease System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium
- 2018-10-12
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(CARMEN CD 306).
- Crohn’s disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Estonia, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, Portugal, Slovakia, Spain, Switzerland, Ukraine, United States
- 2018-05-15
Authorised
- Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-01-31
Authorised
- Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-01-30
Authorised
- Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-01-30
Authorised
- Study to treat the molecular relapsed of AML patients in childhood with Azacitidine
- Intravenous azacitidine 100 mg/m2, Days 1 to 7 of a 28-day cycle for up to 3 cycles initially. In case of decline of MRD during azacitidine treatment additional cycles are allowed (maximum 6 cycles). ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Austria, Belgium, Czech Republic, Denmark, European Union, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Slovakia, Sweden, Switzerland, United Kingdom
- 2017-11-13
Authorised
- A phase 2 Dose-finding study of IMU-838 in patients with active Crohn’s disease
- Crohn’s disease (CD) MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
- Bulgaria, Croatia, Czech Republic, Germany, Netherlands, Poland, Romania, Russian Federation, Serbia, Slovenia, Spain, Ukraine, United Kingdom, United States
- 2019-06-03
Authorised
- Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
- Patients with chromosome Philadelphia positive (Ph+) in chronic phase mielogenus leukemia (CP CML) MedDRA version: 18.0 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Spain
- 2015-02-09
